MSMark L. Schultz

Mark L. Schultz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark L. Schultz has a total of 106 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew P. Lieberman

    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA

    6 shared publications
  • Beverly L. Davidson

    Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children’s Hospital of Philadelphia, Philadelphia, USA

    4 shared publications
  • Luis Tecedor

    The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children’s Hospital of Philadelphia, Philadelphia, PA 19104, United States

    4 shared publications
  • Andrew P. Lieberman

    2 shared publications
  • Colleen S. Stein

    Department of Internal Medicine, Fraternal Order of Eagles Diabetes Research Center, Abboud Cardiovascular Research Center, Carver College of Medicine (N.H.W., J.M.H., J.M.M., C.S.S., J.-Y.Y., B.L., R.L.B.), University of Iowa

    2 shared publications
  • Hayley S. McLoughlin

    Department of Neurology, University of Michigan Medical School, Ann Arbor, Michigan, USA

    2 shared publications

Latest Publications

  • Open Access

    Developing and Characterizing a Murine Model of In Utero Transmission of Ebola Virus

    by Hanora Van Ert, Corey W. Henderson, Brian J. Smith, Paige T. Donovan, Ethan Kardin, Emma Eubank, Maryam Fakhimi, Matthew Liebermann, Kelly N. Messingham, Mark K. Santillan, et al.

    Ebola virus (EBOV) disease (EVD) is a hemorrhagic disease caused by EBOV infection. EVD outcomes in pregnant women are similar to non-pregnant women however, EVD is associated with negative fetal outcomes in ∼99% of cases. There is a critical need for a tractable small animal model to study maternal/fetal transmission of EBOV. We utilized interferon α/β receptor knock out mice infected and authentic EBOV or the model virus, recombinant vesicular stomatitis virus encoding EBOV glycoprotein (rVSV/EBOV). Infection with either virus during late pregnancy resulted in placental infection and vertical transmission to the fetus within 2-3 days. Robust levels of maternal and fetal proinflammatory cytokines were evident by day 5 after EBOV infection. Within the placenta, trophoblasts and endothelial cells were viral antigen positive. Elimination of the endosomal receptor NPC1 in junctional zone trophoblasts reduced placental infection and virus transmission to the fetus. These studies establish an infectious model that provides EBOV trafficking and pathogenesis insights during pregnancy. Teaser: This model provides key insights into how viral trafficking and maternal immune responses drive adverse fetal outcomes during gestational Ebola virus infection.

  • Open Access

    Codon-optimized Npc1 mRNA corrects Niemann-Pick type C1 disease phenotypes in vitro and in vivo

    by Ellen R. Koufer, Alice Townsend, Youngseo Na, Adele B. Correia, Noah K. Latham, Koralege C. Pathmasiri, Olga Ilnytska, Judith Storch, Kyle A. Sullivan, Troy Halseth, et al.


  • Endogenous Protein–Protein Interaction Network of the NPC Cholesterol Transporter 1 in the Cerebral Cortex

    by Roshan Javanshad, Thu T. A. Nguyen, Ruth D. Azaria, Wenping Li, Daisy Edmison, Liang-Wei Gong, Swetha Gowrishankar, Andrew P. Lieberman, Mark L. Schultz, Stephanie M. Cologna

    NPC intracellular cholesterol transporter 1 (NPC1) is a multipass, transmembrane glycoprotein mostly recognized for its key role in facilitating cholesterol efflux. Mutations in the NPC1 gene result in Niemann-Pick disease, type C (NPC), a fatal, lysosomal storage disease. Due to the progressively expanding implications of NPC1-related disorders, we investigated endogenous NPC1 protein-protein interactions in the mouse cortex and human-derived iPSCs neuronal models of the disease through coimmunoprecipitation-coupled with LC-MS based proteomics. The current study investigated protein-protein interactions specific to the wild-type and the most prevalent NPC1 mutation (NPC1I1061T) while filtering out any protein interactor identified in the Npc1-/- mouse model. Additionally, the results were matched across the two species to map the parallel interactome of wild-type and mutant NPC1I1061T. Most of the identified wild-type NPC1 interactors were related to cytoskeleton organization, synaptic vesicle activity, and translation. We found many putative NPC1 interactors not previously reported, including two SCAR/WAVE complex proteins that regulate ARP 2/3 complex actin nucleation and multiple membrane proteins important for neuronal activity at synapse. Moreover, we identified proteins important in trafficking specific to wild-type and mutant NPC1I1061T. Together, the findings are essential for a comprehensive understanding of NPC1 biological functions in addition to its classical role in sterol efflux.


  • Open Access

    Species-specific differences in NPC1 protein trafficking govern therapeutic response in Niemann-Pick type C disease

    by Mark L. Schultz, Kylie J. Schache, Ruth D. Azaria, Esmée Q. Kuiper, Steven Erwood, Evgueni A. Ivakine, Nicole Y. Farhat, Forbes D. Porter, Koralege C. Pathmasiri, Stephanie M. Cologna, et al.

    The folding and trafficking of transmembrane glycoproteins are essential for cellular homeostasis and are compromised in many diseases. In Niemann-Pick type C disease, a lysosomal disorder characterized by impaired intracellular cholesterol trafficking, the transmembrane glycoprotein NPC1 misfolds due to disease-causing missense mutations. While mutant NPC1 has emerged as a robust target for proteostasis modulators, drug development efforts have been unsuccessful in mouse models. Here, we demonstrated unexpected differences in trafficking through the medial Golgi between mouse and human I1061T-NPC1, a common disease-causing mutant. We established that these distinctions are governed by differences in the NPC1 protein sequence rather than by variations in the endoplasmic reticulum–folding environment. Moreover, we demonstrated direct effects of mutant protein trafficking on the response to small molecules that modulate the endoplasmic reticulum–folding environment by affecting Ca ++ concentration. Finally, we developed a panel of isogenic human NPC1 iNeurons expressing WT, I1061T-, and R934L-NPC1 and demonstrated their utility in testing these candidate therapeutics. Our findings identify important rules governing mutant NPC1’s response to proteostatic modulators and highlight the importance of species- and mutation-specific responses for therapy development.


  • Open Access

    Enrichment of NPC1-deficient cells with the lipid LBPA stimulates autophagy, improves lysosomal function, and reduces cholesterol storage

    by Olga Ilnytska, Kimberly Lai, Kirill Gorshkov, Mark L. Schultz, Bruce Nguyen Tran, Maciej Jeziorek, Thaddeus J. Kunkel, Ruth D. Azaria, Hayley S. McLoughlin, Miriam Waghalter, et al.


  • Open Access

    Fbxo2 mediates clearance of damaged lysosomes and modifies neurodegeneration in the Niemann-Pick C brain

    by Elaine A. Liu, Mark L. Schultz, Chisaki Mochida, Chan Chung, Henry L. Paulson, Andrew P. Lieberman

    A critical response to lysosomal membrane permeabilization (LMP) is the clearance of damaged lysosomes through a selective form of macroautophagy known as lysophagy. Although regulators of this process are emerging, whether organ- and cell-specific components contribute to the control of lysophagy remains incompletely understood. Here, we examined LMP and lysophagy in Niemann-Pick type C (NPC) disease, an autosomal recessive disorder characterized by the accumulation of unesterified cholesterol within late endosomes and lysosomes, leading to neurodegeneration and early death. We demonstrated that NPC human fibroblasts show enhanced sensitivity to lysosomal damage as a consequence of lipid storage. Moreover, we described a role for the glycan-binding F-box protein 2 (Fbxo2) in CNS lysophagy. Fbxo2 functions as a component of the S phase kinase-associated protein 1–cullin 1–F-box protein (SKP1-CUL1-SCF) ubiquitin ligase complex. Loss of Fbxo2 in mouse primary cortical cultures delayed clearance of damaged lysosomes and decreased viability after lysosomal damage. Moreover, Fbxo2 deficiency in a mouse model of NPC exacerbated deficits in motor function, enhanced neurodegeneration, and reduced survival. Collectively, our data identified a role for Fbxo2 in CNS lysophagy and establish its functional importance in NPC.


  • Open Access

    Synthetic high-density lipoprotein nanoparticles for the treatment of Niemann–Pick diseases

    by Mark L. Schultz, Maria V. Fawaz, Ruth D. Azaria, Todd C. Hollon, Elaine A. Liu, Thaddeus J. Kunkel, Troy A. Halseth, Kelsey L. Krus, Ran Ming, Emily E. Morin, et al.

    Background: Niemann–Pick disease type C is a fatal and progressive neurodegenerative disorder characterized by the accumulation of unesterified cholesterol in late endosomes and lysosomes. We sought to develop new therapeutics for this disorder by harnessing the body’s endogenous cholesterol scavenging particle, high-density lipoprotein (HDL).Methods: Here we design, optimize, and define the mechanism of action of synthetic HDL (sHDL) nanoparticles.Results: We demonstrate a dose-dependent rescue of cholesterol storage that is sensitive to sHDL lipid and peptide composition, enabling the identification of compounds with a range of therapeutic potency. Peripheral administration of sHDL toNpc1 I1061Thomozygous mice mobilizes cholesterol, reduces serum bilirubin, reduces liver macrophage size, and corrects body weight deficits. Additionally, a single intraventricular injection into adultNpc1 I1061Tbrains significantly reduces cholesterol storage in Purkinje neurons. Since endogenous HDL is also a carrier of sphingomyelin, we tested the same sHDL formulation in the sphingomyelin storage disease Niemann–Pick type A. Utilizing stimulated Raman scattering microscopy to detect endogenous unlabeled lipids, we show significant rescue of Niemann–Pick type A lipid storage.Conclusions: Together, our data establish that sHDL nanoparticles are a potential new therapeutic avenue for Niemann–Pick diseases.


  • Cell biological defects in juvenile neuronal ceroid lipofuscinosis

    by Mark Schultz

    Mutations in the CLN3 gene cause Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), a form of Batten disease that is grouped within the broad class of lysosomal storage diseases. JNCL displays a primary central nervous system phenotype characterized by rapid onset blindness, wide spread brain atrophy and reversal of learned abilities with death occurring 10-20 years after symptom onset. The mechanisms underlying these phenotypes are not known. CLN3 encodes CLN3, a protein with no known molecular function. CLN3 is expressed at very low levels natively in most cells, and is highly hydrophobic. Similar to other lysosomal storage diseases, it is difficult to ascertain the primary versus the secondary defects when the protein functions along the endosomal-lysosomal pathway. In JNCL one common finding among several labs, in various cellular systems, is a fluid-phase endocytotic defect. I took this commonality as a key to CLN3 function, and pursued cell biological pathways required for fluid-phase endocytosis. Fluid-phase endocytosis is regulated by cycling of the small GTPase Cdc42 and I discovered increased Cdc42-GTP in CLN3-null mouse brain endothelial cells. In mouse brain endothelial cells enhanced Cdc42-GTP increased Cdc42 dependent signaling, filopodial formation, and retarded cell migration. I also found reduced plasma membrane association of ARHGAP21, a known negative regulator of Cdc42. My data supports a model where loss of CLN3 reduces ARHGAP21 plasma membrane recruitment, and causes aberrant Cdc42 activation. Thus irregular Cdc42 activation underlies the commonly reported fluid-phase endocytic defects in JNCL. Therapeutic development for JNCL has been hampered in part from the varying phenotypes ascribed to CLN3 deficiency. My discovery that the fluid-phase endocytic defects result from Cdc42 pathway aberrations, which in turn contributed to multiple downstream phenotypes, opened the door to novel JNCL therapeutics. Here I present work showing that a Cdc42 inhibitor corrects the Cdc42 dependent defects in vitro and multiple defects in a JNCL mouse model.

  • Open Access

    Coordinate regulation of mutant NPC1 degradation by selective ER autophagy and MARCH6-dependent ERAD

    by Mark L. Schultz, Kelsey L. Krus, Susmita Kaushik, Derek Dang, Ravi Chopra, Ling Qi, Vikram G. Shakkottai, Ana Maria Cuervo, Andrew P. Lieberman

    Niemann–Pick type C disease is a fatal, progressive neurodegenerative disorder caused by loss-of-function mutations in NPC1, a multipass transmembrane glycoprotein essential for intracellular lipid trafficking. We sought to define the cellular machinery controlling degradation of the most common disease-causing mutant, I1061T NPC1. We show that this mutant is degraded, in part, by the proteasome following MARCH6-dependent ERAD. Unexpectedly, we demonstrate that I1061T NPC1 is also degraded by a recently described autophagic pathway called selective ER autophagy (ER-phagy). We establish the importance of ER-phagy both in vitro and in vivo, and identify I1061T as a misfolded endogenous substrate for this FAM134B-dependent process. Subcellular fractionation of I1061T Npc1 mouse tissues and analysis of human samples show alterations of key components of ER-phagy, including FAM134B. Our data establish that I1061T NPC1 is recognized in the ER and degraded by two different pathways that function in a complementary fashion to regulate protein turnover.


  • Open Access

    Modulating membrane fluidity corrects Batten disease phenotypes in vitro and in vivo

    by Mark L. Schultz, Luis Tecedor, Elena Lysenko, Shyam Ramachandran, Colleen S. Stein, Beverly L. Davidson